Fevipiprant, a selective prostaglandin-D2 receptor-2 antagonist, inhibits human group-2 innate lymphoid cell aggregation and function

Fevipiprant is a potent inhibitor of PGD2-mediated ILC2 activation. The findings support further development as a therapeutic intervention for asthma. (Source: Journal of Allergy and Clinical Immunology)

from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2EgEnWq